Advertisements

Valsartan +pharma

Quick links to important sections

Valsartan +pharma

Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Valsartan +pharma

Property Description
Active ingredient Valsartan (INN)
Form Film-coated tablet (Oral route)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
General purpose Reducing systemic vascular resistance
Origin Synthetic compound

What Type of Medicine is Valsartan?

Valsartan is a synthetic, non-peptide compound classified as an Angiotensin II Receptor Blocker (ARB), used as a prescription-only cardiovascular agent.

The medication's identity is defined by its selective antagonism of the Type 1 (AT1) receptor for the hormone Angiotensin II, positioning it as a functional component of the Renin-Angiotensin System (RAS) Inhibitor group. Valsartan is an antihypertensive drug that acts by blocking the Angiotensin II type 1 receptor. This confirms that the primary function of the medicine is to inhibit the action of a powerful constricting hormone in the blood vessels. The ARB class itself is clinically recognized for its role in managing chronic cardiovascular risks, offering a therapeutic alternative to other blood pressure medications.


Composition, Form, and General Purpose

The medication is an orally active, single-agent product supplied typically as a film-coated tablet, with Valsartan as the sole active ingredient.

The drug entity Valsartan (International Nonproprietary Name) is a complex, synthetic substance formulated for ingestion via the oral route. Medicines containing Valsartan are used to reduce the risk of cardiovascular morbidity and mortality, primarily through their action on blood pressure. This indicates that the medicine provides a foundational benefit in lessening the long-term strain on the heart and arteries. A differentiating factor of the ARB class is its targeted action against the RAS pathway, helping to promote Vasodilatation (vessel relaxation) and reduce systemic vascular resistance. This action ultimately lessens the chronic hemodynamic burden associated with chronic Hypertension and Heart Failure.

Advertisements

What side effects are possible with Valsartan +pharma?

Possible side effects and safety information

This section describes the officially documented adverse effects and safety characteristics of Valsartan, organized according to governmental regulatory standards.

Adverse Reaction Scope and Classification

Adverse reactions are formally categorized by frequency and the body's physiological system affected (System-Organ Class). The most frequently reported effects are typically classified as Common in regulatory documentation, including Dizziness, Headache, and Fatigue. Effects such as Vertigo and Nausea are generally classified as Uncommon.

Adverse events related to official System-Organ Classes include effects on Nervous system disorders (e.g., dizziness), Vascular disorders (e.g., hypotension), Gastrointestinal disorders (e.g., diarrhea, abdominal pain), and Musculoskeletal disorders (e.g., back pain, arthralgia).

Serious Adverse Reactions and Safety Constraints

Certain effects are highlighted as Serious Adverse Reactions in official documentation. These include Angioedema (swelling of the face, lips, tongue, and/or throat) and the potential for Renal Impairment/Failure, particularly in susceptible patients. Regulatory labels also contain high-level safety constraints:

  • Fetal Toxicity: Valsartan is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury and death.
  • Hypersensitivity: The medicine should not be used in individuals with a known hypersensitivity to the active substance.
  • Dual RAS Inhibition: Coadministration with another inhibitor of the Renin-Angiotensin System (RAS), such as Aliskiren, is generally not recommended in certain high-risk individuals, due to increased safety risks like hypotension and hyperkalemia.

Population and Exposure-Related Notes

The safety profile includes Population-Specific Safety Considerations, such as the need for close monitoring of renal function and serum potassium in patients with severe renal impairment or caution in those with severe hepatic impairment. Furthermore, official regulatory text notes that Hypotension may be more frequently observed at the start of treatment or during dose changes in certain patient populations.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the Valsartan overdose profile by its potential for severe hemodynamic instability, which is an exaggerated extension of its intended effect. The most likely manifestation of overdosage is hypotension (low blood pressure), which may be accompanied by tachycardia (rapid heart rate) or, less commonly, bradycardia (slow heart rate).

Documented Severe Outcomes and Required Actions

Outcome or Action Official Regulatory Statement
Severe Outcomes Overdose can result in profound hypotension, shock, and circulatory collapse
Antidote Status No specific antidote is available for the reversal of Valsartan overdose
Procedural Steps Management consists of symptomatic and supportive treatment, which may include placing the patient in a supine position if symptomatic hypotension occurs
Dialysis Note Valsartan is not removed from the plasma by dialysis (hemodialysis)

Immediate medical attention is required for any suspected overdosage or the manifestation of symptomatic hypotension. Regulatory guidance states that if symptomatic hypotension occurs, supportive treatment must be instituted to maintain the patient’s vital signs. For management of a suspected overdose, it is required to contact a poison control center or emergency services.

Advertisements

Therapeutic Uses of Valsartan +pharma

Main uses of Valsartan +pharma

Valsartan +pharma belongs to a class of medications known as angiotensin II receptor blockers (ARBs). It is primarily used to manage conditions related to the cardiovascular system by helping to relax blood vessels, which facilitates easier blood flow and reduces the workload on the heart.

Treatment of high blood pressure

The most common application of this medication is the management of essential hypertension (high blood pressure) in adults and children. By blocking the action of angiotensin II—a hormone that naturally causes blood vessels to tighten—valsartan allows the vessels to widen. This process helps lower blood pressure levels toward a more stable range.

Management of heart failure

Valsartan +pharma is used in patients with heart failure, a condition where the heart muscle is unable to pump blood as efficiently as it should. It is typically prescribed when patients cannot tolerate other types of heart medications, such as ACE inhibitors, or may be used alongside other therapies to improve heart function and reduce the frequency of hospitalizations related to heart failure symptoms.

Post-heart attack recovery

For individuals who have recently experienced a myocardial infarction (heart attack), this medication may be prescribed to improve survival rates and long-term outcomes. Treatment is often initiated shortly after a heart attack to help protect the heart muscle and prevent further complications or the development of heart failure.

Benefits and therapeutic goals

The primary objective of treatment with Valsartan +pharma is to reduce the risk of serious cardiovascular events. By maintaining lower blood pressure and supporting heart function, the medication contributes to:

  • Reduction of cardiovascular risk: Lowering blood pressure helps decrease the likelihood of experiencing strokes or further heart attacks.
  • Improved heart efficiency: In heart failure patients, the medication assists in managing symptoms and improving the overall quality of life by reducing the strain on the cardiac system.
  • Long-term organ protection: Controlling hypertension is essential for protecting the kidneys and other vital organs from the damage associated with chronically high blood pressure.
Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults for all approved indications.
  • Pediatric patients aged 1 year and older for the treatment of Hypertension.
  • Older adults (no initial dose adjustment is required).

Populations for whom use is contraindicated:

  • Pregnant women during the second and third trimesters (due to fetal toxicity).
  • Patients with known hypersensitivity to Valsartan or any component.
  • Patients with severe hepatic impairment, biliary cirrhosis, or cholestasis.
  • Patients with Diabetes Mellitus who are taking aliskiren.

Age-Related and Organ Function Eligibility

  • Infants (< 1 year): Use is not recommended (safety and efficacy not established).
  • Pediatric Renal Impairment: Use is not recommended in children with a glomerular filtration rate < 30 mL/min/1.73 m² or on dialysis.
  • Volume/Salt Depletion: This condition must be corrected before starting treatment to mitigate the risk of symptomatic hypotension.
  • Lactation: Use is not recommended while breastfeeding.

Connection to the Overall Eligibility Profile

Official regulatory documents define Valsartan eligibility by establishing contraindications for populations with high absolute risk (fetal toxicity, severe liver disease) and setting restrictions for conditional use (volume depletion, renal function) that must be managed according to label requirements.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the clinically significant interactions officially documented for valsartan-containing products.

Dual Blockade of the Renin-Angiotensin System (RAS)

Co-administration with other medicines that block the RAS is generally avoided due to the increased risk of hypotension, hyperkalemia (high blood potassium), and changes in kidney function. This restriction includes combining valsartan with other Angiotensin II Receptor Blockers (ARBs), Angiotensin-Converting Enzyme (ACE) Inhibitors, or Direct Renin Inhibitors (DRIs) like aliskiren.

  • Specific Constraint: Co-administration with aliskiren is contraindicated in patients with diabetes or moderate-to-severe kidney impairment.

Potassium-Elevating Agents

Concomitant use with agents that can raise serum potassium must be approached with caution as it increases the risk of hyperkalemia. These include potassium-sparing diuretics (e.g., spironolactone, triamterene), potassium supplements, salt substitutes containing potassium, and certain other agents like heparin.

Other Clinically Relevant Interactions

Interacting Product Category Key Constraint/Requirement
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May reduce the blood pressure-lowering effect and increase the risk of kidney function impairment, especially in elderly or volume-depleted patients.
Lithium Use requires careful monitoring as an increase in serum lithium concentrations and toxicity has been reported.
Specific Transport Inhibitors Co-administration with inhibitors of certain hepatic transporters (OATP1B1, MRP2), such as cyclosporine or ritonavir, may increase the body's exposure to valsartan.

Note: Specific valsartan combination products (e.g., with Sacubitril) carry an absolute contraindication against co-use with an ACE inhibitor, requiring a 36-hour washout period before initiation.

Advertisements

Mechanism of Action

Valsartan functions as a selective and competitive Angiotensin II type 1 ( AT1) receptor antagonist. It exhibits high affinity for the AT1 receptor, which is prominently located on vascular smooth muscle, adrenal glands, and renal tissues. By binding to the AT1 receptor, Valsartan prevents Angiotensin II ( Ang II), a primary ligand and potent vasoconstrictor, from initiating its signaling cascade.

This blockade interrupts the typical intracellular response triggered by Ang II binding, which involves the activation of Gq proteins and subsequent increases in intracellular calcium concentration. The consequence of AT1 inhibition is the functional suppression of Ang II activity. At the system level, this mechanism leads to the prevention of Ang II-mediated vasoconstriction and a corresponding reduction in aldosterone secretion. This physiological modulation results in vasodilation and decreased sodium and water retention.

Advertisements

Dosage and Administration Information

How to Use Valsartan +pharma

Valsartan is a medication used in accordance with established protocols concerning the route, schedule, and dosage.

Administration and Dosage Principles

Administration of Valsartan is via the oral route. It is supplied as film-coated tablets in strengths including 40 mg, 80 mg, 160 mg, and 320 mg. The medication may be taken with or without food, offering flexibility in its daily administration. To ensure appropriate blood levels, it is generally recommended to take the dose at the same time each day.

Indication Standard Adult Dosing Schedule Dosing Frequency
Hypertension Initial 80 mg or 160 mg; Max 320 mg daily Once daily
Heart Failure & Post-MI Initial 40 mg (HF) or 20 mg (Post-MI); Target 160 mg Twice daily (BID)

Titration and Special Instructions

The required dose frequency is indication-dependent, requiring once-daily use for hypertension, but twice-daily use for heart failure and post-myocardial infarction care. Treatment often begins with low starting doses, followed by a gradual upward adjustment, or titration, to reach the specified target dose. For conditions like heart failure, dose adjustments are conducted at intervals of at least two weeks to assess tolerability.

Special limitations apply to certain patient populations; for instance, the dose must not exceed 80 mg daily in adult patients with mild-to-moderate non-cholestatic hepatic impairment. If a dose is missed, the standard procedure is to skip the missed dose and resume the regular schedule, without taking a double dose to compensate.

Advertisements

Recent Clinical Evidence

Valsartan +pharma: Recent Clinical Evidence

Evidence for use in Managing High Blood Pressure

Valsartan research involved large-scale, long-term Randomized Controlled Trials (RCTs) set up to explore its use in adults with high blood pressure, monitoring changes in systolic and diastolic blood pressure and the incidence of major cardiovascular outcomes like stroke and heart attack. Findings describe patterns observed in the studies related to achieving blood pressure goals. A key research limitation is that long-term comparisons were typically made against an active medication, not against an inactive placebo pill.

Evidence for use in Care of Heart Failure

For chronic heart failure, Valsartan was studied for use in international RCTs to evaluate outcomes related to all-cause mortality and morbidity, including hospitalization for heart failure. Data for certain combinations remain insufficient; specifically, studies noted that adding Valsartan to a regimen already including an ACE inhibitor and a beta-blocker was associated with adverse patterns without substantial difference in outcomes.

Evidence Following a Heart Attack with Left Ventricular Dysfunction

Research evaluated Valsartan for use in clinically stable adults following a heart attack who presented with left ventricular dysfunction. Large trials compared Valsartan monotherapy against an established ACE inhibitor monotherapy. While data showed patterns related to patient survival in both monotherapy groups, combining the two agents was associated with an increased incidence of adverse effects and no additional benefit was observed.

Long-Term Studies, Specific Groups, and Uncertainties

Most major Valsartan research incorporated long-term follow-up periods, often extending from three to four years, contributing to understanding long-term outcome patterns. Evidence also exists for use in older adults and specific pediatric populations (one year and older). However, long-term effects are not fully established in children. Research gaps include the lack of placebo-controlled data in long-term hypertension trials and uncertainties regarding specific combination regimens.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Valsartan +pharma (FAQ)

Q: Is Valsartan +pharma considered a 'water pill' or something else?

A: Valsartan is classified as an Angiotensin II Receptor Blocker (ARB), not a 'water pill' (diuretic). This class of medicine works by blocking a powerful hormone that causes blood vessels to constrict, which ultimately results in the relaxation of the vessels and a reduction in blood pressure.


Q: What is the typical timeframe before a doctor might change the Valsartan +pharma dosage?

A: According to official prescribing information, the full blood pressure reduction is typically seen within 4 weeks of starting treatment for hypertension. For certain indications like heart failure, dose adjustments are often conducted at intervals of at least two weeks, reflecting the time needed to assess its effect and tolerability.


Q: Why did my doctor prescribe Valsartan +pharma instead of another blood pressure drug?

A: Valsartan is an Angiotensin II Receptor Blocker (ARB) and is often prescribed as an alternative to another class of drugs called ACE inhibitors. A common reason for this choice is that ARBs like Valsartan are typically not associated with causing a dry cough, which can be a side effect of ACE inhibitors.


Q: What foods or supplements should be avoided while on Valsartan +pharma?

A: Regulatory documents indicate that caution is advised with products that can raise blood potassium levels, as this medication may also cause an increase. Specifically, potassium supplements and salt substitutes that contain potassium should be approached with care. Additionally, high doses of certain supplements like fish oil may increase the risk of low blood pressure.


Q: What are the signs that Valsartan +pharma might be causing a serious side effect?

A: Serious adverse reactions mentioned in regulatory documents include angioedema, which is rapid swelling of the face, lips, tongue, or throat. Patients are advised to monitor for signs such as severe low blood pressure (intense dizziness or fainting) or changes in urination, as these can be indicators of issues like kidney impairment.


Q: What are the requirements for monitoring bloodwork while on Valsartan +pharma?

A: Monitoring of serum potassium and renal (kidney) function is generally recommended according to official product information. This is especially important for people who have existing kidney impairment or heart failure, or who are taking other medications that can also affect potassium levels.


Q: Does alcohol interact negatively with Valsartan +pharma?

A: Regulatory information indicates that alcohol may cause additive effects with Valsartan, meaning both substances lower blood pressure. This may increase the likelihood of symptoms like dizziness, lightheadedness, or fainting, particularly when treatment is first started.


Q: Can a person stop taking Valsartan +pharma suddenly, or does it require tapering?

A: Discontinuation of the medication is generally not recommended without consulting a healthcare provider. In patients being treated for conditions like heart failure or after a heart attack, continued therapy is important to maintain the cardiovascular benefits this medicine provides.


Q: Is there a list of common side effects for Valsartan +pharma to watch out for?

A: The most common side effects reported in clinical trials for hypertension include headache, dizziness, fatigue, and viral infection. For heart failure, dizziness, hypotension (low blood pressure), and diarrhea are frequently observed. These effects are reported as common but should be discussed with a healthcare provider if they are concerning.


Q: What are the typical benefits of Valsartan +pharma beyond just lowering blood pressure?

A: Beyond its primary role in reducing high blood pressure, studies show that Valsartan is also indicated to reduce the risk of hospitalization for heart failure. Additionally, it is used to lower the risk of cardiovascular mortality in stable patients who have recently had a heart attack and have left ventricular dysfunction.


Q: Is Valsartan +pharma safe for people who have liver problems?

A: The use of Valsartan is contraindicated (absolutely prohibited) for people with severe liver problems, biliary cirrhosis, or cholestasis. The dose must also be limited to a maximum of 80 mg daily for adults with mild-to-moderate non-cholestatic liver impairment, per regulatory guidelines.


Q: What research is available on the safety of Valsartan +pharma during pregnancy?

A: Official warnings state that medicines acting on the Renin-Angiotensin System can cause fetal injury and death. Due to this risk, Valsartan is contraindicated during the second and third trimesters of pregnancy. This constraint reflects the potential risks of fetal injury and death associated with the drug class.


Q: Why is Valsartan +pharma often combined with a diuretic?

A: Valsartan is frequently combined with diuretics to help achieve greater and more comprehensive control of blood pressure. Using this combination is a common practice in managing hypertension, and its effectiveness is supported by data from clinical studies.


Q: Can Valsartan +pharma cause changes in heart rate?

A: Clinical trial data shows that treatment with Valsartan typically results in essentially no change in heart rate. While low blood pressure (hypotension) is a possible side effect, and this can sometimes indirectly influence heart rate, the medication does not generally cause direct changes to heart rhythm.


Q: Are there any specific medical conditions that absolutely prohibit the use of Valsartan +pharma?

A: Yes, regulatory documents list several conditions that prohibit use, known as contraindications. These include a known hypersensitivity to the drug, pregnancy (second and third trimesters), and using it alongside the medication aliskiren if the patient has diabetes or kidney impairment.


Q: Does Valsartan +pharma require any special storage instructions?

A: Valsartan tablets must be stored at Controlled Room Temperature, which is typically 20 C to 25 C (68 F to 77 F). The medication should be kept in a closed container, protected from excessive heat, moisture, direct light, and must not be frozen.


Q: Can Valsartan +pharma cause difficulty sleeping or insomnia?

A: Difficulty sleeping or insomnia is not listed among the most common adverse reactions reported in clinical trials. It is, however, an effect that has been reported in post-marketing experience. If this or any other effect is experienced, it should be discussed with a healthcare provider.


Q: What should a person do if they double-dosed on Valsartan +pharma by mistake?

A: The most likely sign of an accidental overdose is significant low blood pressure (hypotension), which may be accompanied by a rapid heart rate (tachycardia). If an overdose is suspected, immediate professional medical attention is advised.


Q: Is Valsartan +pharma used for conditions other than high blood pressure and heart failure?

A: Yes, in addition to treating hypertension and heart failure, official guidelines indicate its use for patients who are clinically stable after a heart attack and have left ventricular dysfunction. This usage is intended to reduce cardiovascular mortality.


Q: What is the main reason a doctor would discontinue Valsartan +pharma?

A: A doctor may choose to discontinue Valsartan due to the development of an intolerable side effect, such as persistent and severe dizziness or headache. Other reasons include clinically significant renal dysfunction (kidney impairment) or symptomatic hypotension (low blood pressure) that cannot be managed.


Q: Can Valsartan +pharma be crushed or split if it's hard to swallow?

A: Valsartan is supplied as film-coated tablets. The manufacturer does provide instructions for pharmacists on how to prepare an extemporaneous oral suspension for patients who have trouble swallowing the tablets whole. Patients are not generally advised to crush or split the tablet themselves.


Q: Is it necessary to avoid grapefruit juice while taking Valsartan +pharma?

A: Official drug interaction documents indicate that Valsartan is not known to interact negatively with grapefruit or grapefruit juice. This is unlike some other blood pressure medications which may have specific restrictions related to grapefruit consumption.

Advertisements

How should Valsartan +pharma be stored and disposed of?

Valsartan tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The tablets should be kept in a closed container, away from excessive heat, moisture, and direct light, and must be protected from freezing.

Stability and Handling

The extemporaneously prepared oral suspension requires unique conditions: it must be shaken well before use and is stable for up to 30 days at room temperature (below 30 C) or up to 75 days under refrigeration (2 C to 8 C). The suspension should be stored in a glass bottle with a child-resistant cap.

Disposal and Safety

All Valsartan products must be kept out of the reach of children. For disposal, patients should ask a healthcare professional or pharmacist how to discard any unused or expired medicine, ensuring the process is in accordance with all local and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valsartan +pharma found in:

A-Z Index: